Andreas Struengmann

Holzkirchen, Germany

Andreas Struengmann

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 153(Granted Patents)

Forward Citations (Not Self Cited) = 144(Sep 21, 2024)


Years Active: 2001

where 'Filed Patents' based on already Granted Patents

1 patent (USPTO):

Introduction

Andreas Struengmann is a prominent inventor based in Holzkirchen, Germany, known for his contributions to the field of pharmaceuticals. With a focus on enhancing drug efficacy, he holds a significant patent that addresses the challenges of solubility and bioavailability in medication, particularly in relation to the anti-inflammatory agent meloxicam.

Latest Patents

Struengmann's most notable patent, titled "Pharmaceutical compositions of meloxicam with improved solubility and bioavailability," encompasses innovative compositions that utilize enolic carboxamide type anti-inflammatory agents. This patent specifically details formulations that enhance wettability, aqueous solubility, and dissolution behavior across a diverse pH range. By employing modifications to the crystal structure of meloxicam through both dry and wet mechanical homogenization, these formulations achieve improved bioavailability and effectiveness, ultimately benefiting patients requiring anti-inflammatory treatment.

Career Highlights

Struengmann's career is marked by his association with Hexal AG, a company renowned for its commitment to developing high-quality pharmaceutical products. His inventive work has significantly contributed to advancements in drug formulations, showcasing his expertise in pharmaceuticals and his dedication to improving patient outcomes.

Collaborations

Throughout his career, Andreas Struengmann has collaborated with notable colleagues, including Brigitte Freudensprung and Karin Klokkers. These partnerships have facilitated the exchange of ideas and fostered innovations, furthering the development of pharmaceutical compositions that address critical healthcare needs.

Conclusion

In summary, Andreas Struengmann stands out as an inventive force in the pharmaceutical industry. His patent on meloxicam formulations represents a substantial advance in medicine, aimed at improving the efficacy of treatments for patients. As he continues his work at Hexal AG, his contributions will undoubtedly influence the future of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…